Unloxcyt

Active Ingredient(s): Cosibelimab-ipdl
FDA Approved: * December 13, 2024
Pharm Company: * CHECKPOINT THERAPEUTICS INC
Category: Cancer
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Unloxcyt 300 mg/5ml Intravenous Injection, Solution
NDC: 70095-130
Labeler:
Sun Pharmaceutical Industries, Inc.
Unloxcyt 300 mg/5ml Intravenous Injection, Solution
NDC: 83444-301
Labeler:
Checkpoint Therapeutics, Inc.